Canton Barry 4

What Happened Canton Barry, a reported 10% owner of Ginkgo Bioworks (DNA), reported the conversion of 251,786 performance-based restricted stock units (PSUs) into Class A common shares on April 9, 2026 (code M). Following the conversion, 124,727 shares were sold in an open-market transaction on April 10, 2026 at $6.43 per share, generating proceeds of approximately $802,494. The sale was reported on a Form 4 filed April 13, 2026.

Key Details

• Transaction dates: April 9, 2026 (PSU conversion/exercise), April 10, 2026 (open-market sale).
• Sale: 124,727 shares at $6.43, total proceeds ≈ $802,494.
• Conversion: 251,786 PSUs converted to shares (one PSU = one share).
• Origin of PSUs: 375,800 PSUs granted June 19, 2025; actual payout = 67% of target, resulting in 251,786 vested shares (375,800 × 67%).
• The sale was described as a "sell-to-cover" by the reporting person’s spouse to satisfy tax withholding obligations (footnote: non-discretionary, per company plan).
• Shares owned after the transactions are not specified in the provided filing.
• Filing: Form 4 filed April 13, 2026 (no late filing flag indicated).

Context

• The conversion (code M) reflects PSUs vesting and being converted into shares rather than a cash option exercise. A portion of those shares was sold to cover tax withholding (sell-to-cover), which issuers commonly require and which footnote F2 indicates was executed by the reporting person’s spouse and not a discretionary sale.
• For retail investors: this is largely a routine, tax-related sale following a performance-based award vesting, not necessarily a directional insider "sell for diversification" or a discretionary trade by the reporting person. As a 10% owner, the filing is a required disclosure of the spouse’s vested award and subsequent sell-to-cover transaction.